Immunovant, Inc. (IMVT) Earnings History
Net Loss9 years of earnings data (2018–2026) · Currently unprofitable on a TTM basis
Loading earnings history...
Immunovant, Inc. (IMVT) Earnings Overview
As of June 23, 2026, Immunovant, Inc. (IMVT) reported trailing twelve-month net income of -$506M, reflecting -1.5% year-over-year growth. The company earned $-2.48 per diluted share over the past four quarters.
Looking at the long-term picture, IMVT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$448 in fiscal 2019.
Immunovant, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARDX (-$58M net income, -15.1% margin), RCUS (-$369M net income, -142.9% margin), VKTX (-$472M net income), IMVT has comparable earnings metrics. Compare IMVT vs ARDX →
IMVT Earnings vs Peers
Earnings metrics vs comparable public companies
IMVT Historical Earnings Data (2018–2026)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2026 | -$506M | -22.2% | -$533M | $-2.77 | - | - |
| 2025 | -$414M | -59.6% | -$438M | $-2.73 | - | - |
| 2024 | -$259M | -22.9% | -$270M | $-1.88 | - | - |
| 2023 | -$211M | -34.6% | -$208M | $-1.71 | - | - |
| 2022 | -$157M | -45.9% | -$156M | $-1.43 | - | - |
| 2021 | -$107M | -61.8% | -$108M | $-1.22 | - | - |
| 2020 | -$66M | -14818650.0% | -$60M | $-1.54 | - | - |
| 2019 | $-448 | +100.0% | $-450 | $0.00 | - | - |
| 2018 | -$137M | - | -$137M | $-13.67 | - | - |
Download Data
Export IMVT earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
IMVT — Frequently Asked Questions
Quick answers to the most common questions about buying IMVT stock.
What is IMVT earnings per share (EPS)?
IMVT trailing twelve-month (TTM) diluted EPS is $-2.48, reflecting -1.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2026 is available in the table on this page.
What is Immunovant, Inc.'s net income?
Immunovant, Inc. (IMVT) trailing twelve-month net income is $-506M as of 2026. Earnings declined -1.5% year-over-year.
Is IMVT profitable?
IMVT is not currently profitable on a TTM basis, reporting a net loss of $-506M. Net margin is N/A. Investors should monitor for a return to profitability.
What is IMVT's earnings growth rate?
IMVT compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2026.
What are IMVT's profit margins?
Immunovant, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -64.8%.
Is IMVT growing earnings?
IMVT earnings growth is slowing. Current YoY EPS growth of -1.5% trails the 5-year CAGR of N/A. TTM net income is $-506M.
What was IMVT's best earnings year?
Immunovant, Inc.'s highest annual net income on record is $-448.00, achieved in fiscal year 2019. Earnings history on this page spans 2018 to 2026 and includes all annual and quarterly figures.
What were IMVT's earnings last quarter?
IMVT's most recent reported quarter was Q4 2026. Net income was $-148M with diluted EPS of $-0.73. For a full breakdown of all quarters, see the quarterly earnings table on this page.